NRSN
NeuroSense Therapeutics Ltd.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
NeuroSense Therapeutics Ltd.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
No changes.
No changes.
Annual filing, covered
20-F parsed · Mar 31 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
20-F parsed · Mar 31 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Largest filed tie
0
filed ties
—
—
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for NeuroSense Therapeutics Ltd..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for NeuroSense Therapeutics Ltd..
News
Expected move
No implied move.
NeuroSense Therapeutics Ltd.
1.31
+0.03 · +2.50%
| Manager | Value | % base | |
|---|---|---|---|
| UBS | $78,218 | 27.28% | +121.27% |
| Independent Advisor Alliance | $72,000 | 25.11% | +100.00% |
| Yorkville Advisors Global | $56,160 | 19.59% | 0.00% |
| Commonwealth Equity Services | $16,400 | 5.72% | 0.00% |
| PNC Financial Services | $15,228 | 5.31% | 0.00% |
| Manager | Value | % base | |
|---|---|---|---|
| UBS | $78,218 | 27.28% | +121.27% |
| Independent Advisor Alliance | $72,000 | 25.11% | +100.00% |
| Yorkville Advisors Global | $56,160 | 19.59% | 0.00% |
| Commonwealth Equity Services | $16,400 | 5.72% | 0.00% |
| PNC Financial Services | $15,228 | 5.31% | 0.00% |
+40.90%
shares held · 10 largest managers